Q-omics provides the consensus-scored DEFB109D profile across patient tissues and cancer cell-line models. DEFB109D expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DEFB109D is differentially expressed in 4, with the highest sampling consensus in CHOL. Additionally, DEFB109D RNA expression shows 9,766 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, CHOL, and GBM as cancer lineages where DEFB109D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB109D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB109D survival associations across molecular data types. DEFB109D RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB109D RNA expression–survival associations across cancer types. High DEFB109D expression shows unfavorable associations in STAD, PAAD and DLBC, but favorable associations in HNSC, BLCA and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for DEFB109D RNA expression.
This table summarizes DEFB109D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB109D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB109D shows lower tumor expression in BRCA and higher tumor expression in CHOL, LIHC and LUSC. The CHOL box plot shows higher DEFB109D RNA expression in tumor versus normal tissue (log2 FC = +1.495, t-test p < 0.001).
This table shows molecular features associated with DEFB109D in patient tissues and cancer cell lines. In patient samples, DEFB109D shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
